Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mcgovern, M. E
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Use of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome

Mark E Mcgovern

2200 North Commerce Parkway, Suite 300 Weston, Florida 33326 — 3258 USA, mmcgovern{at}kospharm.com

This paper will focus on the use of nicotinic acid as a therapeutic option for cardiovascular risk reduction in patients with abnormal glucose metabolism and `atherogenic dyslipidaemia'. This is characterised by low levels of HDL-C, high triglycerides, and preponderance of small, dense LDL particles. Whilst nicotinic acid may increase plasma glucose in some patients, more recent studies show that the effect of nicotinic acid on glycaemic control is minimal in the majority of patients, and that nicotinic acid decreases the risk of cardiac events in patients with elevated fasting glucose, diabetes, or metabolic syndrome.

Key Words: dyslipidaemia • IFG • diabetes metabolic syndrome • nicotinic acid.

The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 2, 78-85 (2004)
DOI: 10.1177/14746514040040020301
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Diabetes and Vascular Disease ResearchHome page
E. Windler, M. Schoffauer, and B.-C. Zyriax
The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease
Diabetes and Vascular Disease Research, June 1, 2007; 4(2): 136 - 142.
[Abstract] [PDF]

Home page
 Diabetes and Vascular Disease ResearchHome page
T. R Pedersen, G. Assmann, J.-P. Bassand, M J. Chapman, R. Erbel, and C. Sirtori
Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment
Diabetes and Vascular Disease Research, September 1, 2006; 3(2_suppl): S1 - S12.
[Abstract] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
L. F Van Gaal, F. Peiffer, and D. Ballaux
Reducing cardiovascular risk in patients with type 2 diabetes: the potential contribution of nicotinic acid
The British Journal of Diabetes & Vascular Disease, November 1, 2005; 5(6): 344 - 350.
[Abstract] [PDF]

Home page
 Eur Heart J SupplHome page
C. A. Reasner
Niaspan(R): a powerful treatment option for 'diabetic dyslipidaemia'
Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F48 - F55.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
P. Barter
Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus: The Pan-Asian Consensus Panel On Hdl-C
The British Journal of Diabetes & Vascular Disease, March 1, 2005; 5(2_suppl): S1 - S15.
[Abstract] [PDF]